

U.S. Biosimilars Market

As of August 2023



Class	Supportive Care			Oncology			TNF Blockers			Insulin	Ophthalmology	Multiple Sclerosis
Molecule	Filgrastim	Epoetin	Pegfilgrastim	Rituximab	Bevacizumab	Trastuzumab	Infliximab	Etanercept	Adalimumab	Insulin Glargine	Ranibizumab	Natalizumab
Innovator	Neupogen (Amgen)	Epogen/Procrit (Amgen / JnJ)	Neulasta (Amgen)	Rituxan (Genetech)	Avastin (Genetech)	Herceptin (Genetech)	Remicade (JnJ)	Enbrel (Amgen)	Humira (AbbVie)	Lantus (Sanofi)	Lucentis (Genentech)	Tysabri (Biogen)
Launched Manufacturer Launch Date	Zarxio Sandoz Sep 2015 Nivestym Pfizer Oct 2018 Releuko Amneal Mar 2022	Retacrit Pfizer/Vifor Nov 2018	Fulphila Biocon Jul 2018 Udenyca Coherus Jan 2019 Ziextenzo Sandoz Nov 2019 Nyvepria Pfizer Dec 2020 Stimufend Fresenius Kabi Feb 2023 Fylnetra Amneal May 2022	Truxima Teva Nov 2019 Ruxience Pfizer Jan 2020 Riabni Amgen Jan 2021	Mvasi Amgen Jul 2019 Zirabev Pfizer Jan 2020 Vegzelma Celltrion Sep 2022	Kanjinti Amgen Jul 2019 Ogivri Biocon Nov 2019 Trazimera Pfizer Feb 2020 Ontruzant Organon Apr 2020	Inflectra Pfizer Nov 2016 Renflexis Organon Jul 2018 Avsola Amgen Jul 2020 Ixifi Pfizer Dec 2014	Ongoing litigation forecasted launch 2028/2029 Erelzi Sandoz Aug 2016 Eticovo Samsung Aug 2019	Biosimilars referencing Humira will launch in 2023 Amjevita Amgen Feb 2023 Abrilada Pfizer Jul 2023 Hyrimoz** Sandoz Mar 2023 Cyltezo BI Jul 2023 Hadlima*** Samsung Bioepis July 2023	INT Semglee Biocon Nov 2021 INT Rezvoglar Eli Lilly Dec 2021	Byooviz Biogen Jun 2022 INT Cimerli Coherus Aug 2022 Interchangeability designation	Tyruko Sandoz Aug 2023
Approved Manufacturer FDA Approval Date												

**A high concentrate (March 2023) and low concentrate (October 2018) version are approved.

***A high concentrate (August 2022) and low concentrate (July 2019) version are approved.